

2019

Li X, Frechem S, Moi D, Lehr T, Taubert M, Hsin CH, Mikus G, Neuvoven PJ, Olkkola KT, Saari TI, Fuhr U. *A Physiological based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Interaction of CYP₃A₄, Genetic Polymorphisms of CYP₂C₁₉ and prediction of Drug-Drug Interaction.* Clinical Pharmacokinetics 59, 781-808

Lemke C, Christmann J, Yin J, Alonso JM, Serrano E, Chioua M, Ismaili L, Martínez-Grau MA, Beadle CD, Vetman T, Dato FM, Bartz U, Elsinghorst PW, Pietsch M, Müller CE, Iriepa I, Wille T, Marco-Contelles J, Gütschow M. *Chromenones as Multi-Neurotargeting Inhibitors of Human Enzymes.* ACS Omega 2019, 4 22161-22168

Klepac K, Yang J, Hildebrand S, Pfeifer A. *RGS2: A multifunctional signaling hub that balances brown adipose tissue function and differentiation.* Mol Metab. 2019 Dec; 30:173-183. doi: 10.1016/j.molmet.2019.09.015.

Claff T, Yu J, Blais V, Patel N, Martin C, Wu L, Han GW, Holleran BJ, Van der Poorten O, White KL, Hanson MA, Sarret P, Gendron L, Cherezov V, Katritch V, Ballet S, Liu ZJ, Müller CE, Raymond C, Stevens RC. *Elucidating the active δ-opioid receptor crystal structure with peptide and small-molecule agonists.* Sci. Adv. 2019, 5, eaax9115.

Singh S, Nazabal A, Kaniyappan S, Pellequer JL, Wolberg AS, Imhof D, Oldenburg J, Biswas A. *The plasma Factor XIII heterotetrameric complex structure: unexpected unequal pairing within a symmetric complex.* Biomolecules, 9(12), 765

Wißbrock A, Goradia NB, Kumar A, Paul George AA, Küh T, Bellstedt P, Ramachandran, R, Hoffmann P, Galler K, Popp J, Neugebauer U, Hampel K, Zimmermann B, Adam S, Wiendl M, Krönke G, Hamza I, Heinemann SH, Frey S, Hueber AJ, Ohlenschläger O, Imhof D. *Structural insights into heme binding to IL-36α proinflammatory cytokine.* Sci. Rep., 9, 16893

Kumar A, Bellstedt P, Wiedemann C, Wißbrock A, Imhof D, Ramachandran R, Ohlenschläger O. *NMR experiments on the transient interaction of the intrinsically disordered N-terminal peptide of cystathionine-β-synthase with heme.* J. Magn. Reson., 308, 106561

Nassir M, Mirza S, Arad U, Lee SY, Rafehi M, Attha IY, Renn C, Zimmermann H, Pelletier J, Sévigny J, Müller CE, Fischer B. *Adenine-(methoxy)-ethoxy-P_{α,α}-dithio-triphosphate inhibits pathologic calcium pyrophosphate deposition in osteoarthritic human chondrocytes.* Org. Biomol. Chem. 2019, 17, 9913-9923.

Wantoch von Rekowski K, König P, Henze S, Schlesinger M, Zawierucha P, Januchowski R, Bendas G. *The Impact of Integrin-Mediated Matrix Adhesion on Cisplatin Resistance of W1 Ovarian Cancer Cells.* Biomolecules 2019.

Undap NIJ, Papu A, Chillo D, Gruber F, Kaligis F, Lepar M, Hertzner C, Böhringer N, König GM, Schäferle TF, Wägele H. *First survey of heterobranch sea slugs (Mollusca, Gastropoda) from the island Sangihe, North Sulawesi, Indonesia.* Diversity, 2019, 11, 170.

Tietze D, Kaufmann D, Tietze AA, Voll A, Reher R, König GM, Hausch F. *Structural and dynamical basis of G protein inhibition by YM-254890 and FR900359: an inhibitor in action.* J. Chem. Inf. Model, 2019, 59, 4363-4373

Küppers J, Hympánová M, Keuler T, Schneider AJ, Schnakenburg G, Gütschow M. *Transformation of the Carboxyl Group of an Amino Acid to Variously Substituted Imidazoles through a Davidson-type Heterocyclization.* Synthesis 2019, 51, 1961-1068.

Martinez-Lagunas K, Yamaguchi Y, Becker C, Geiger C, DeRuiter MC; Miura M, Fleischmann BK, Hesse M. *In vivo detection of programmed cell death during mouse heart development.* Cell & Death Differentiation; 27, 1398-1414

Bäuml C A, Imhof D. Tridegin as FXIIIa inhibitor. Zedira GmbH, Blog Entry:
https://zedira.com/Blog/Tridegin-as-FXIIIa-inhibitor_118

Küppers J, Benkel T, Annala S, Schnakenburg G, Kostenis E, Gütschow M. *BIM-46174 Fragments as Potential Ligands of G Proteins.* Med. Chem. Commun. 2019, 10, 1838-1843.

Singh S, Dodd J, Volkers P, Hethershaw E, Philippou H, Ivaskevicius V, Imhof D, Oldenburg J, Biswas A. Structure functional insights into calcium binding during the activation of coagulation factor XIII A. Sci. Rep., 9, 11324

Bhattarai S, Pippel J, Meyer A, Freundlieb M, Schmies C, Abdelrahman A, Fiene A, Lee SY, Zimmermann H, El Tayeb A, Yegutkin GG, Sträter N, Müller CE. *X-ray co-crystal structure guides the way to subnanomolar competitive ecto-5'-nucleotidase (CD73) inhibitors for cancer immunotherapy.* Adv. Therap. 2019, 190075, 1-8.

Paul George AA, Heimer P, Leipold E, Schmitz T, Kaufmann D, Tietze D, Heinemann SH, Imhof D. *Effect of Conformational Diversity on the Bioactivity of μ -Conotoxin PIIIA Disulfide Isomers.* Mar. Drugs, 17(7), 390

Marx D, Schnakenburg G, Grimme S, Christa E. Müller CE. *Structural and conformational studies on carboxamides of 5,6-diaminouracils – precursors of biologically active xanthine derivatives.* Molecules 2019, 24, 1-16.

Lui R, Li X, Wei J, Lui S, Chnag Y, Zhang J, Zhang J, Zhang X, Fuhr U, Taubert M, Tian X. *A Single Dose of Baicalin Has No clinically significant Effect on the Pharmacokinetics of Cyclosporin A in Healthy Chinese Volunteers.* Front Pharmacol 10, 518

Lindner S, Steinebach C, Kehm H, Mangold M, Gütschow M, Kröhnke J. *Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTASCs.* J. Vis. Exp. 2019, 147 e59472

Lui R, Li X, Wei Y et al. *A single dose of Baicalin has no clinically significant effect on the pharmacokinetics of cyclosporin A in healthy Chinese volunteers.* Front Pharmacol. 2019 May 14; 10:518

Steinebach C, Sosic I, Lindner S, Bricelj A, Kohl F, Ng YLD, Monschke M, Wagner KG, Krönke J, Gütschow M. *A MedChem toolbox for cereblon-directed PROTACs.* Med. Chem. Commun. 2019, 10, 1037-1041

Malfacini D, Patt J, Annala S, Harpsøe K, Eryilmaz F, Reher R, Crüsemann M, Hanke W, Zhang H, Tietze D, Gloriam DE, Bräuner-Osborne H, Strømgaard K, König GM, A. Inoue A, Gomeza J, Kostenis E. *Rational design of a heterotrimeric G protein α subunit with artificial inhibitor sensitivity.* J. Biol. Chem. 2019, 294, 5757-5758

Nassir M, Mirza S, Arad U, Lee Sy, Rafehi M, Attah JY, Renn C, Zimmermann H, Pelletier J, Sévigny J, Müller CE, Fischer B. *Identification of adenine-N9-(methoxy)-ethyl-β-bisphosphonate as NPP1 inhibitor attenuates NPPase activity in human osteoarthritic chondrocytes.* Purinergic Signalling, 15:247-263

Bäuml CA, Schmitz T, Paul Georg AA, Sudarsanam M, Hardes K, Steinmetzer T, Holle AL, Wolberg AS, Pötzsch B, Oldenburg J, Biswas A, Imhof D. *Coagulation Factor XIIa Inhibitor Tridegin: On the Role of Disulfide Bonds for Folding, Stability, and Function.* J. Med. Chem. April 2019; 62: 3513-3523

Annala S, Feng X, Shridhar N, Eryilmaz F, Patt J, Yang YH, Pfeil EM, Cervantes-Villagrana RD, Inoue A, Häberlein F, T. Slodczyk T, Reher R, Kehraus S, Monteleone S, Schrage R, Heycke N, Rick U, Engel E, Pfeifer A, Kolb P, König GM, M. Büinemann M, Tütting T, Vázquez-Prado J, Gutkind JS, Gaffal E, Kostenis E. *Direct targeting of Gaq and Ga11 oncoproteins in cancer cells.*

Jiang J, Seel CJ, Temirak A, Namasivayam V, Arridu A, Schabikowski J, Baqi Y, Hinz S, Hockeeyer J, Müller C E. *A_{2B} Adenosine receptor antagonists with picomolar potency.* J. Med. Chem. 2019, 62, 4032-4055.

Junker A, Renn C, Dobelmann C, Namasivayam V, Jain S, Losenkova K, Irjala H, Duca S, Balasubramanian R, Chakraborty S, Börgel F, Zimmermann H, Yegutkin G, Müller CE, Kenneth Jacobson K. *Structure-activity relationship of purine and pyrimidine nucleotides as ecto-5'-nucleotidase (CD73) inhibitors.* J. Med. Chem. 2019, 62, 3677-3695

Li X, Zoller M, Fuhr U et al. *Ciprofloxacin in critically ill subjects: Considering hepatic function, age and sex to choose the optimal dose.* J Antimicrob Chemother 2019; 74: 682-690

Bueschbell B, Barreto CAV, Prteo AJ, Schiedel AC, Moreira IS. *A complete Assessment of Dopamine Receptor-Ligand Interactions through Computational Methods.* Molecules 2019, 24, 1196

Bäuml CA, Schmitz T, Paul George AA, Sudarsanam M, Hardes K, Steinmetzer T, Holle L A, Wolberg, SA, Pötzsch B, Oldenburg J, Biswas A, Imhof D. *Coagulation Factor XIIa Inhibitor Tridegin: On the Role of Disulfide Bonds for Folding, Stability, and Function.* J. Med. Chem., 62(7), 3513-3523

Marx D, Wingen LM, Schnakenburg G, Müller CE, Scholz MS: *Fast, efficient, and versatile synthesis of 6-amino-5-carboxamidouracils as precursors for 8-substituted xanthines.* *Front. Chem.* 2019, 7, 1-15; doi: 10.3389/fchem.2019.00056.

Junkert A, Renn C, Dobelmann C, Namasivayam V, Jain S, Losenkova K, Irlala H, Ducca S, Balasubramanian R, Chakraborty S, Börgel F, Zimmermann H, Yeguthin GG, Müller CE, Jacobs KA. *Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) inhibitors.* *J. Med. Chem.* 2019; 62; 3677-3695

Kumar A, Wißbrock A, Bellstedt P, Lang A, Ramachandran R, Wiedemann C, Imhof D, Ohlenschläger O. *1H, 13C, and 15N resonance assignments of the cytokine interleukin-36β isoform-2.* *Biomol. NMR. Assign.*, 13(1), 155-161

Steinebach C, Kehm H, Lindner S, Vu LP, Köpff S, Lózep Mármol A, Weiler C, Wagner KG, Krönke J, Gütschow M. *PROTAC-mediated crosstalk between E3 ligases.* *Chem. Commun.* 2019, 55, 1821-1824

Fuhr U, Hsin C, Li X et al. *Assessment of pharmacokinetic drug-drug interaction in Humans: In Vivo probe substrates for drug metabolism and drug transport revisited.* *Annu Rev Pharmacol Toxicol* 2019; 59: 507-36

Wißbrock A, Paul George AA, Brewitz HH, Kühl T, Imhof D. The Molecular Basis of Transient Heme-Protein Interactions: Analysis, Concept and Implementation. *Biosci. Rep.*, 39(1), BSR20181940